Work

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Year: 2023

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2023-178090

Authors: Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari, Amir T. Fathi, Kapil N. Bhalla, Samuel Agresta, Sarah Reilly, Caroline Almon, Murphy Hentemann, Denice Hickman, Dillon Corrigan, Meghan Macaraeg, Jessica Piel, Kim Horrigan, Salah Nabhan, Paul Martin, Eytan M. Stein

Institutions: The University of Texas MD Anderson Cancer Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Massachusetts General Hospital, Foghorn Therapeutics (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Chromatin Remodeling and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389220735

Cites:

Cited by: 20

Related to: 10